Epirus Biopharmaceuticals, Inc., a biosimilar company developing and commercializing monoclonal antibodies (mAbs), has acquired Bioceros Holding B.V., a biopharmaceutical company developing mAbs, for $14.1 million in cash and stock payable in installments over a one-year period.

Under the deal, Epirus expands its biosimilar pipeline with acquisition of three preclinical product candidates: BOW080, a proposed biosimilar to eculizumab (reference biologic, Alexion Pharmaceuticals' Soliris); BOW090, a proposed biosimilar to ustekinumab (reference biologic, Janssen's Stelara); and BOW100, a proposed biosimilar to golimumab (reference biologic, Janssen's Simponi). The anticipated filing dates for the three new pipeline products are 2020 for BOW080, 2021 for BOW090, and 2022 for BOW100.

Eculizumab is indicated to treat the rare blood disorders, paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Ustekinumab and golimumab are both intended indicated to treat inflammatory and immune mediated disorders.

Source: Epirus Biopharmaceuticals